Opus Genetics Inc reports results for the quarter ended June 30 - Earnings Summary

Opus Genetics

11/08/2026 12:59

Opus Genetics Inc IRD.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of nineteen analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -27 cents to -9 cents per share.
Revenue fell 73.8% to $755.00 thousand from a year ago; analysts expected $2.47 million. 
Opus Genetics Inc's reported EPS for the quarter was a loss of 14 cents​.
The company reported a quarterly loss of $8.1 million.
Opus Genetics Inc shares had fallen by 10.9% this quarter and gained 82.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 6.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Opus Genetics Inc is $10.00, about 63.4% above its last closing price of $3.66
This summary was machine generated from LSEG data August 11 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.16
-0.14
Beat
Mar. 31 2026 
-0.14
-0.75
Missed
Dec. 31 2025 
-0.12
-0.29
Missed
Sep. 30 2025 
-0.13
-0.25
Missed